Skip to main content
Top
Published in: Respiratory Research 1/2018

Open Access 01-12-2018 | Research

An attempt at modeling COPD epidemiological trends in France

Authors: Pierre-Régis Burgel, Caroline Laurendeau, Chantal Raherison, Claire Fuhrman, Nicolas Roche

Published in: Respiratory Research | Issue 1/2018

Login to get access

Abstract

Background

Anticipating the future burden of chronic obstructive pulmonary disease (COPD) is required to develop adequate public health policies.

Methods

A dynamic population model was built to estimate COPD prevalence by 2025 using data collected during the most recent large general population study on COPD prevalence in France (2005) as baseline values. Sensitivity analyses were performed to test the effect of variations in key input variables.

Results

The model predicted a steady increase in crude COPD prevalence among subjects aged≥45 years from 2005 (prevalence estimate: 84.51‰) to 2025 (projected prevalence: 95.76‰, + 0.56‰/yr). There was a 4-fold increase in the prevalence of GOLD grade 3–4 cases, a 23% relative increase in women and a 21% relative increase in subjects ≥75 years. In sensitivity analyses, these temporal trends were robust. Factors associated with > 5% relative variations in projected 2025 prevalence estimates were baseline prevalence and severity distribution, incidence in women and severity of incident cases, transition rates between severity grades, and mortality.

Conclusions

Projections of future COPD epidemiology consistently predict an increase in the prevalence of moderate-to-very severe COPD, especially due to increases among women and subjects aged ≥75 years. Developing robust prediction models requires collecting reliable data on current COPD epidemiology.
Appendix
Available only for authorised users
Literature
1.
go back to reference Tabberer M, Gonzalez-McQuire S, Muellerova H, Briggs AH, Rutten-van Molken M, Chambers M, Lomas DA. Development of a conceptual model of disease progression for use in economic modeling of chronic obstructive pulmonary disease. Med Decis Mak. 2017;37:440–52.CrossRef Tabberer M, Gonzalez-McQuire S, Muellerova H, Briggs AH, Rutten-van Molken M, Chambers M, Lomas DA. Development of a conceptual model of disease progression for use in economic modeling of chronic obstructive pulmonary disease. Med Decis Mak. 2017;37:440–52.CrossRef
2.
go back to reference Zafari Z, Bryan S, Sin DD, Conte T, Khakban R, Sadatsafavi M. A systematic review of health economics simulation models of chronic obstructive pulmonary disease. Value Health. 2017;20:152–62.CrossRefPubMed Zafari Z, Bryan S, Sin DD, Conte T, Khakban R, Sadatsafavi M. A systematic review of health economics simulation models of chronic obstructive pulmonary disease. Value Health. 2017;20:152–62.CrossRefPubMed
4.
go back to reference Srivastava K, Thakur D, Sharma S, Punekar YS. Systematic review of humanistic and economic burden of symptomatic chronic obstructive pulmonary disease. Pharmacoeconomics. 2015;33:467–88.CrossRefPubMed Srivastava K, Thakur D, Sharma S, Punekar YS. Systematic review of humanistic and economic burden of symptomatic chronic obstructive pulmonary disease. Pharmacoeconomics. 2015;33:467–88.CrossRefPubMed
5.
go back to reference Ramsey SD, Sullivan SD. The burden of illness and economic evaluation for COPD. Eur Respir J Suppl. 2003;41:29s–35s.CrossRefPubMed Ramsey SD, Sullivan SD. The burden of illness and economic evaluation for COPD. Eur Respir J Suppl. 2003;41:29s–35s.CrossRefPubMed
6.
go back to reference Toy EL, Gallagher KF, Stanley EL, Swensen AR, Duh MS. The economic impact of exacerbations of chronic obstructive pulmonary disease and exacerbation definition: a review. Copd. 2010;7:214–28.CrossRefPubMed Toy EL, Gallagher KF, Stanley EL, Swensen AR, Duh MS. The economic impact of exacerbations of chronic obstructive pulmonary disease and exacerbation definition: a review. Copd. 2010;7:214–28.CrossRefPubMed
7.
go back to reference Atsou K, Chouaid C, Hejblum G. Variability of the chronic obstructive pulmonary disease key epidemiological data in Europe: systematic review. BMC Med. 2011;9:7.CrossRefPubMedPubMedCentral Atsou K, Chouaid C, Hejblum G. Variability of the chronic obstructive pulmonary disease key epidemiological data in Europe: systematic review. BMC Med. 2011;9:7.CrossRefPubMedPubMedCentral
8.
go back to reference Rosenberg SR, Kalhan R, Mannino DM. Epidemiology of chronic obstructive pulmonary disease: prevalence, morbidity, mortality, and risk factors. Semin Respir Crit Care Med. 2015;36:457–69.CrossRefPubMed Rosenberg SR, Kalhan R, Mannino DM. Epidemiology of chronic obstructive pulmonary disease: prevalence, morbidity, mortality, and risk factors. Semin Respir Crit Care Med. 2015;36:457–69.CrossRefPubMed
9.
go back to reference Salvi SS, Barnes PJ. Chronic obstructive pulmonary disease in non-smokers. Lancet. 2009;374:733–43.CrossRefPubMed Salvi SS, Barnes PJ. Chronic obstructive pulmonary disease in non-smokers. Lancet. 2009;374:733–43.CrossRefPubMed
10.
go back to reference Meiners S, Eickelberg O, Konigshoff M. Hallmarks of the ageing lung. Eur Respir J. 2015;45:807–27.CrossRefPubMed Meiners S, Eickelberg O, Konigshoff M. Hallmarks of the ageing lung. Eur Respir J. 2015;45:807–27.CrossRefPubMed
11.
go back to reference Roche N, Dalmay F, Perez T, Kuntz C, Vergnenegre A, Neukirch F, Giordanella JP, Huchon G. Impact of chronic airflow obstruction in a working population. Eur Respir J. 2008;31:1227–33.CrossRefPubMed Roche N, Dalmay F, Perez T, Kuntz C, Vergnenegre A, Neukirch F, Giordanella JP, Huchon G. Impact of chronic airflow obstruction in a working population. Eur Respir J. 2008;31:1227–33.CrossRefPubMed
12.
go back to reference Casanova C, Marin JM, Martinez-Gonzalez C, de Lucas-Ramos P, Mir-Viladrich I, Cosio B, Peces-Barba G, Calle-Rubio M, Solanes-Garcia I, Aguero R, et al. New GOLD classification: longitudinal data on group assignment. Respir Res. 2014;15:3.CrossRefPubMedPubMedCentral Casanova C, Marin JM, Martinez-Gonzalez C, de Lucas-Ramos P, Mir-Viladrich I, Cosio B, Peces-Barba G, Calle-Rubio M, Solanes-Garcia I, Aguero R, et al. New GOLD classification: longitudinal data on group assignment. Respir Res. 2014;15:3.CrossRefPubMedPubMedCentral
13.
go back to reference Hoogendoorn M, Rutten-van Molken MP, Hoogenveen RT, van Genugten ML, Buist AS, Wouters EF, Feenstra TL. A dynamic population model of disease progression in COPD. Eur Respir J. 2005;26:223–33.CrossRefPubMed Hoogendoorn M, Rutten-van Molken MP, Hoogenveen RT, van Genugten ML, Buist AS, Wouters EF, Feenstra TL. A dynamic population model of disease progression in COPD. Eur Respir J. 2005;26:223–33.CrossRefPubMed
14.
15.
go back to reference Pelkonen M, Notkola IL, Nissinen A, Tukiainen H, Koskela H. Thirty-year cumulative incidence of chronic bronchitis and COPD in relation to 30-year pulmonary function and 40-year mortality: a follow-up in middle-aged rural men. Chest. 2006;130:1129–37.CrossRefPubMed Pelkonen M, Notkola IL, Nissinen A, Tukiainen H, Koskela H. Thirty-year cumulative incidence of chronic bronchitis and COPD in relation to 30-year pulmonary function and 40-year mortality: a follow-up in middle-aged rural men. Chest. 2006;130:1129–37.CrossRefPubMed
16.
17.
go back to reference Mannino DM, Buist AS, Petty TL, Enright PL, Redd SC. Lung function and mortality in the United States: data from the first National Health and nutrition examination survey follow up study. Thorax. 2003;58:388–93.CrossRefPubMedPubMedCentral Mannino DM, Buist AS, Petty TL, Enright PL, Redd SC. Lung function and mortality in the United States: data from the first National Health and nutrition examination survey follow up study. Thorax. 2003;58:388–93.CrossRefPubMedPubMedCentral
18.
go back to reference Feenstra TL, van Genugten ML, Hoogenveen RT, Wouters EF, Rutten-van Molken MP. The impact of aging and smoking on the future burden of chronic obstructive pulmonary disease: a model analysis in the Netherlands. Am J Respir Crit Care Med. 2001;164:590–6.CrossRefPubMed Feenstra TL, van Genugten ML, Hoogenveen RT, Wouters EF, Rutten-van Molken MP. The impact of aging and smoking on the future burden of chronic obstructive pulmonary disease: a model analysis in the Netherlands. Am J Respir Crit Care Med. 2001;164:590–6.CrossRefPubMed
19.
go back to reference McLean S, Barbour V, Wild S, Simpson C, Sheikh A. Models for estimating projections for disease prevalence and burden: a systematic review focusing on chronic obstructive pulmonary disease. J Health Serv Res Policy. 2015;20:246–53.CrossRefPubMed McLean S, Barbour V, Wild S, Simpson C, Sheikh A. Models for estimating projections for disease prevalence and burden: a systematic review focusing on chronic obstructive pulmonary disease. J Health Serv Res Policy. 2015;20:246–53.CrossRefPubMed
20.
go back to reference Molinari N, Chanez P, Roche N, Ahmed E, Vachier I, Bourdin A. Rising total costs and mortality rates associated with admissions due to COPD exacerbations. Respir Res. 2016;17:149.CrossRefPubMedPubMedCentral Molinari N, Chanez P, Roche N, Ahmed E, Vachier I, Bourdin A. Rising total costs and mortality rates associated with admissions due to COPD exacerbations. Respir Res. 2016;17:149.CrossRefPubMedPubMedCentral
21.
go back to reference de Marco R, Accordini S, Cerveri I, Corsico A, Anto JM, Kunzli N, Janson C, Sunyer J, Jarvis D, Chinn S, et al. Incidence of chronic obstructive pulmonary disease in a cohort of young adults according to the presence of chronic cough and phlegm. Am J Respir Crit Care Med. 2007;175:32–9.CrossRefPubMed de Marco R, Accordini S, Cerveri I, Corsico A, Anto JM, Kunzli N, Janson C, Sunyer J, Jarvis D, Chinn S, et al. Incidence of chronic obstructive pulmonary disease in a cohort of young adults according to the presence of chronic cough and phlegm. Am J Respir Crit Care Med. 2007;175:32–9.CrossRefPubMed
22.
go back to reference Rennard S, Decramer M, Calverley PM, Pride NB, Soriano JB, Vermeire PA, Vestbo J. Impact of COPD in North America and Europe in 2000: subjects' perspective of confronting COPD international survey. Eur Respir J. 2002;20:799–805.CrossRefPubMed Rennard S, Decramer M, Calverley PM, Pride NB, Soriano JB, Vermeire PA, Vestbo J. Impact of COPD in North America and Europe in 2000: subjects' perspective of confronting COPD international survey. Eur Respir J. 2002;20:799–805.CrossRefPubMed
23.
go back to reference Landis SH, Muellerova H, Mannino DM, Menezes AM, Han MK, van der Molen T, Ichinose M, Aisanov Z, Oh YM, Davis KJ. Continuing to confront COPD international patient survey: methods, COPD prevalence, and disease burden in 2012-2013. Int J Chron Obstruct Pulmon Dis. 2014;9:597–611.PubMedPubMedCentral Landis SH, Muellerova H, Mannino DM, Menezes AM, Han MK, van der Molen T, Ichinose M, Aisanov Z, Oh YM, Davis KJ. Continuing to confront COPD international patient survey: methods, COPD prevalence, and disease burden in 2012-2013. Int J Chron Obstruct Pulmon Dis. 2014;9:597–611.PubMedPubMedCentral
24.
go back to reference Roche N, Ajjouri R, Compagnon A, Van Der Molen T, Mullerova H. French data from the continuing to confront COPD (C2C) survey. Rev Mal Respir. 2017;34:180–7.CrossRefPubMed Roche N, Ajjouri R, Compagnon A, Van Der Molen T, Mullerova H. French data from the continuing to confront COPD (C2C) survey. Rev Mal Respir. 2017;34:180–7.CrossRefPubMed
25.
go back to reference Similowski T, Boucot I, Piperno D, Huchon G. Chronic obstructive pulmonary disease in France: the patients' perspective. Results of an international survey (confronting COPD). Presse Med. 2003;32:1403–9.PubMed Similowski T, Boucot I, Piperno D, Huchon G. Chronic obstructive pulmonary disease in France: the patients' perspective. Results of an international survey (confronting COPD). Presse Med. 2003;32:1403–9.PubMed
26.
go back to reference McLean S, Hoogendoorn M, Hoogenveen RT, Feenstra TL, Wild S, Simpson CR, Molken MR, Sheikh A. Projecting the COPD population and costs in England and Scotland: 2011 to 2030. Sci Rep. 2016;6:31893.CrossRefPubMedPubMedCentral McLean S, Hoogendoorn M, Hoogenveen RT, Feenstra TL, Wild S, Simpson CR, Molken MR, Sheikh A. Projecting the COPD population and costs in England and Scotland: 2011 to 2030. Sci Rep. 2016;6:31893.CrossRefPubMedPubMedCentral
27.
go back to reference Hoogendoorn M, Rutten-van Molken MP, Hoogenveen RT, Al MJ, Feenstra TL. Developing and applying a stochastic dynamic population model for chronic obstructive pulmonary disease. Value Health. 2011;14:1039–47.CrossRefPubMed Hoogendoorn M, Rutten-van Molken MP, Hoogenveen RT, Al MJ, Feenstra TL. Developing and applying a stochastic dynamic population model for chronic obstructive pulmonary disease. Value Health. 2011;14:1039–47.CrossRefPubMed
28.
go back to reference Menn P, Leidl R, Holle R. A lifetime Markov model for the economic evaluation of chronic obstructive pulmonary disease. Pharmacoeconomics. 2012;30:825–40.CrossRefPubMed Menn P, Leidl R, Holle R. A lifetime Markov model for the economic evaluation of chronic obstructive pulmonary disease. Pharmacoeconomics. 2012;30:825–40.CrossRefPubMed
Metadata
Title
An attempt at modeling COPD epidemiological trends in France
Authors
Pierre-Régis Burgel
Caroline Laurendeau
Chantal Raherison
Claire Fuhrman
Nicolas Roche
Publication date
01-12-2018
Publisher
BioMed Central
Published in
Respiratory Research / Issue 1/2018
Electronic ISSN: 1465-993X
DOI
https://doi.org/10.1186/s12931-018-0827-7

Other articles of this Issue 1/2018

Respiratory Research 1/2018 Go to the issue